Sanjay Nayak sold $16k of OCUL
Chief Strategy Officer at OCULAR THERAPEUTIX, INC. 1,814 shares at an average of $9.00, traded Nov 25, 2024, filed Nov 27, 2024.
Score components
- +15RoleOfficer
- 0Trade size$16k at market
- 0Share of holdings soldSold 1.0% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -16.1%, 3m -31.0%, 6m -21.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-24-123410, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 25, 2024 | SOpen-market sale Common Stock10b5-1 | -1,814 | $9.00 | $16k | 174,380 | Nov 27, 2024 |
Related signals
Other insiders at OCULAR THERAPEUTIX, INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 11Weak | OCULAR THERAPEUTIX, INC | Jeffrey S. Heier Chief Scientific Officer | $77k 10,869 shares | -3% | |
| 11Weak | OCULAR THERAPEUTIX, INC | Peter Kaiser Chief Development Officer | $70k 9,990 shares | -4% | |
| 20Weak | OCULsell OCULAR THERAPEUTIX, INC | Donald Notman Chief Operating Officer | $11k 1,099 shares | -0% | |
| 21Weak | OCULAR THERAPEUTIX, INC | Pravin Dugel See Remarks | $166k 20,056 shares | -1% | |
| 15Weak | OCULAR THERAPEUTIX, INC | Jeffrey S. Heier Chief Scientific Officer | $25k 3,057 shares | -1% | |
| 10Weak | OCULAR THERAPEUTIX, INC | Peter Kaiser Chief Development Officer | $23k 2,810 shares | -1% | |
| 10Weak | OCULAR THERAPEUTIX, INC | Sanjay Nayak Chief Strategy Officer | $15k 1,759 shares | -1% | |
| 46Moderate | OCULbuy OCULAR THERAPEUTIX, INC | Richard L Lindstrom Md director | $461k 60,229 shares | +32% | |
| 15Weak | OCULAR THERAPEUTIX, INC | Nadia Waheed Chief Medical Officer | $27k 3,510 shares | -1% | |
| 35Weak | OCULAR THERAPEUTIX, INC | Pravin Dugel See Remarks | $1.1M 124,882 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.